In a recent issue of Clinical Science, Prieto-Vicente et al. [Clin. Sci. (2018) 132, 985–1001] have smartly demonstrated a potential new use of cardiotrophin-1 (CT-1) to treat and palliate an inflammatory bowel disease such as ulcerative colitis. In that work, authors report that in ulcerative colitic mice, administration of exogenous recombinant CT-1 (rCT-1) promotes lower colon damage and lower disease activity index, reducing systemic levels of tumor necrosis factor α (TNF-α) and also diminishing TNF-α expression in colon together with the reduction in other common inflammation markers. Besides, in vivo rCT-1 administration induces activation of several molecular pathways, including nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription (STAT)-3, and abolishes bacterial translocation from intestine to other organs, including mesenteric ganglia, lungs, and spleen. Additionally, these results were nicely corroborated in CT-1 depleted mice; in which colon damage and ulcerative colitis severity were greater compared with the wild-type counterparts. All together, these results suggested that CT-1 could be a promising new therapeutic approach for treating inflammatory bowel disease, particularly ulcerative colitis. However, further studies are required to determine its major mechanisms of action and the potential efficacy of CT-1 in human inflammatory bowel diseases.
Skip Nav Destination
Cover ImageIn this issue, Wohlfahrtova et al. report on the link between early isolated v-lesion (eIV) and rejection of kidney allografts. The cover image is a Circos plot that depicts the association between the 15 most signifi cant up-regulated genes between TCMRV (T cell-mediated vascular rejection) and eIV, and signifi cantly enriched pathways and GO terms that play a role in the immune response. For further details, see pages 2269–2284 .
Commentary| October 19 2018
Potential clinical treatment of colitis with cardiotrophin-1
1University of Navarra, Department of Nutrition, Food Science and Physiology, Edificio de Investigación, C/Irunlarrea 1, Pamplona 31008, Spain
2University of Navarra, Centre for Nutrition Research, Faculty of Pharmacy and Nutrition, Edificio de Investigación, C/Irunlarrea 1, Pamplona 31008, Spain
Correspondence: Xavier Escoté (firstname.lastname@example.org)
Search for other works by this author on:
Clin Sci (Lond) (2018) 132 (20): 2169–2174.
May 30 2018
September 05 2018
September 26 2018
This is a commentary on: Cardiotrophin-1 attenuates experimental colitis in mice
Xavier Escoté; Potential clinical treatment of colitis with cardiotrophin-1. Clin Sci (Lond) 31 October 2018; 132 (20): 2169–2174. doi: https://doi.org/10.1042/CS20171626
Download citation file:
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your InstitutionSign in via your Institution
Get Access To This Article
Buy This Article